Raymond James Reinstates Outperform on Immunovant, Announces $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Immunovant (NASDAQ:IMVT) and set a price target of $36.
October 10, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Immunovant with a $36 price target, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating and a $36 price target by Raymond James suggests a positive sentiment towards Immunovant's stock, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100